Full-Body MRI in Patients With an Implantable Cardioverter-Defibrillator Primary Results of a Randomized Study

被引:58
作者
Gold, Michael R. [1 ]
Sommer, Torsten [2 ]
Schwitter, Juerg [3 ]
Al Fagih, Ahmed [4 ]
Albert, Timothy [5 ]
Merkely, Bela [6 ]
Peterson, Michael [7 ]
Ciuffo, Allen [8 ]
Lee, Sung [9 ]
Landborg, Lynn [10 ]
Cerkvenik, Jeffrey [10 ]
Kanal, Emanuel [11 ]
机构
[1] Med Univ S Carolina, Div Cardiol, Charleston, SC 29425 USA
[2] German Red Cross Hosp, Dept Diagnost & Intervent Radiol & Nucl Med, Neuwied, Germany
[3] Univ Lausanne Hosp, Dept CMR, Lausanne, Switzerland
[4] Prince Sultan Cardiac Ctr, Riyadh, Saudi Arabia
[5] Cent Coast Cardiol, Salinas, CA USA
[6] Semmelweis Univ, Ctr Heart, H-1085 Budapest, Hungary
[7] United Heart & Vasc Clin, Minneapolis, MN USA
[8] Sentara Norfolk Gen Hosp, Norfolk, VA USA
[9] Washington Hosp Ctr, Washington, DC 20010 USA
[10] Medtronic, Minneapolis, MN USA
[11] Univ Pittsburgh, Med Ctr, Dept Radiol Neuroradiol, Pittsburgh, PA USA
关键词
implantable cardioverter-defibrillator; magnetic resonance imaging; HEART-FAILURE; TASK-FORCE;
D O I
10.1016/j.jacc.2015.04.047
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND Magnetic resonance imaging (MRI) of patients with conventional implantable cardioverterdefibrillators (ICD) is contraindicated. OBJECTIVES This multicenter, randomized trial evaluated safety and efficacy of a novel ICD system specially designed for full-body MRI without restrictions on heart rate or pacing dependency. The primary safety objective was >90% freedom from MRI-related events composite endpoint within 30 days post-MRI. The primary efficacy endpoints were ventricular pacing capture threshold and ventricular sensing amplitude. METHODS Subjects received either a single-or dual-chamber ICD. In a 2:1 randomization, subjects either underwent MRI at 1.5-T of the chest, cervical, and head regions to maximize radiofrequency exposure up to 2 W/kg specific absorption rate and gradient field exposure to 200 T/m/s per axis (MRI group, n = 175), or they underwent a 1-h waiting period without MRI (control group, n = 88). A subset of MRI patients underwent ventricular fibrillation induction testing post-MRI to characterize defibrillation function. RESULTS In 42 centers, 275 patients were enrolled (76% male, age 60.4 +/- 13.8 years). The safety endpoint was met with 100% freedom from the composite endpoint (p < 0.0001). Both efficacy endpoints were met with minimal differences in the proportion of MRI and control patients who demonstrated a <= 0.5 V increase in ventricular pacing capture threshold (100% MRI vs. 98.8% control, noninferiority p < 0.0001) or a <= 50% decrease in R-wave amplitude (99.3% MRI vs. 98.8% control, noninferiority p = 0.0001). A total of 34 ventricular tachyarrhythmia/ventricular fibrillation episodes (20 induced; 14 spontaneous) occurred in 24 subjects post-MRI, with no observed effect on sensing, detection, or treatment. CONCLUSIONS This is the first randomized clinical study of an ICD system designed for full-body MRI at 1.5-T. These data support that the system is safe and the MRI scan does not adversely affect electrical performance or efficacy. (C) 2015 by the American College of Cardiology Foundation.
引用
收藏
页码:2581 / 2588
页数:8
相关论文
共 21 条
[1]  
[Anonymous], 2012, ISOTS109742012
[2]   Clinical safety of the ProMRI pacemaker system in patients subjected to head and lower lumbar 1.5-T magnetic resonance imaging scanning conditions [J].
Bailey, William M. ;
Rosenthal, Lawrence ;
Fananapazir, Lameh ;
Gleva, Marye ;
Mazur, Alexander ;
Rinaldi, C. A. ;
Kypta, Alexander ;
Merkely, Bela ;
Woodard, Pamela K. .
HEART RHYTHM, 2015, 12 (06) :1183-1191
[3]   Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure [J].
Bardy, GH ;
Lee, KL ;
Mark, DB ;
Poole, JE ;
Packer, DL ;
Boineau, R ;
Domanski, M ;
Troutman, C ;
Anderson, J ;
Johnson, G ;
McNulty, SE ;
Clapp-Channing, N ;
Davidson-Ray, LD ;
Fraulo, ES ;
Fishbein, DP ;
Luceri, RM ;
Ip, JH .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (03) :225-237
[4]   Determining the Risks of Magnetic Resonance Imaging at 1.5 Tesla for Patients With Pacemakers and Implantable Cardioverter Defibrillators [J].
Cohen, Jennifer D. ;
Costa, Heather S. ;
Russo, Robert J. .
AMERICAN JOURNAL OF CARDIOLOGY, 2012, 110 (11) :1631-1636
[5]   Complete loss of ICD programmability after magnetic resonance imaging [J].
Fiek, M ;
Remp, T ;
Reithmann, C ;
Steinbeck, G .
PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 2004, 27 (07) :1002-1004
[6]   Randomized trial of pacemaker and lead system for safe scanning at 1.5 Tesla [J].
Gimbel, J. Rod ;
Bello, David ;
Schmitt, Matthias ;
Merkely, Bela ;
Schwitter, Juerg ;
Hayes, David L. ;
Sommer, Torsten ;
Schloss, Edward J. ;
Chang, Yanping ;
Willey, Sarah ;
Kanal, Emanuel .
HEART RHYTHM, 2013, 10 (05) :685-691
[7]   Preclinical evaluation of implantable cardioverter-defibrillator developed for magnetic resonance imaging use [J].
Gold, Michael R. ;
Kanal, Emanuel ;
Schwitter, Juerg ;
Sommer, Torsten ;
Yoon, Hyun ;
Ellingson, Michael ;
Landborg, Lynn ;
Bratten, Tara .
HEART RHYTHM, 2015, 12 (03) :631-638
[8]   Deaths associated with implantable cardioverter defibrillator failure and deactivation reported in The United States Food and Drug Administration Manufacturer and User Facility Device Experience Database [J].
Hauser, RG ;
Kallinen, L .
HEART RHYTHM, 2004, 1 (04) :399-405
[9]   ACR guidance document on MR safe practices: 2013 [J].
Kanal, Emanuel ;
Barkovich, A. James ;
Bell, Charlotte ;
Borgstede, James P. ;
Bradley, William G., Jr. ;
Froelich, Jerry W. ;
Gimbel, J. Rod ;
Gosbee, John W. ;
Kuhni-Kaminski, Ellisa ;
Larson, Paul A. ;
Lester, James W., Jr. ;
Nyenhuis, John ;
Schaefer, Daniel Joe ;
Sebek, Elizabeth A. ;
Weinreb, Jeffrey ;
Wilkoff, Bruce L. ;
Woods, Terry O. ;
Lucey, Leonard ;
Hernandez, Dina .
JOURNAL OF MAGNETIC RESONANCE IMAGING, 2013, 37 (03) :501-530
[10]  
McAnulty J, 1997, NEW ENGL J MED, V337, P1576